Fundz

Online Disruptive Technologies, Inc. reported raising $50,000 in an initial SEC Form D filing, from an offering of $50,000

PRIVATEMar 08, 2019

Amount Raised

$50,000

$50,000 sold, per SEC Form D (first sale Mar 8, 2019)

Round Type

Pre-Seed

AndoverBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as SAVICELL that raised within 45 days of this round, from Fundz verified event records.

  • CytoRecovery, Inc. raised $500K (Seed) on April 22, 2019.
  • CytoRecovery, Inc. raised $175K (Pre-Seed) on April 22, 2019.
  • ABK Biomedical raised $28M on April 22, 2019.
  • DoubleRainbow Biosciences Inc. raised $3M (Seed) on April 22, 2019.
  • Evofem Biosciences raised $30M on April 22, 2019.
  • Poseida Therapeutics, Inc. raised $142M on April 22, 2019.

Who to call at SAVICELL, and when

A new round usually means SAVICELL is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day SAVICELL raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at SAVICELL, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at SAVICELL. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

SAVICELL

Location

10 STEVENS STREET, PO BOX 1080

Andover, Massachusetts, United States

About

THE IMMUNOBIOPSY™ COMPANY – BECAUSE EARLY DETECTION IS LIFE™ The Savicell™ Well-Shield™ platform is a blood test inherently designed for the early detection of disease. Cancer is our first focus. Savicell™ has a first-in-class liquid ImmunoBiopsy™ platform designed for the early detection of disease. The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. The Company’s initial focus is on the multi-billion dollar, underserved cancer liquid biopsy market. Metabolic changes in the immune system modulate cell fate and function, influencing immune response outcomes. These energy changes give the immune system the ability (effector function) to attack disease, including cancer. Diseases produce unique signatures in immune metabolic profiles that ImmunoBiopsy™ uses to distinguish between and within various ailments, such as cancers, autoimmune diseases, and infectious diseases. Savicell’s Liquid ImmunoBiopsy measures the energy changes of the immune system, which are disease-specific, and identifies the ailment. ​

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment SAVICELL raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsEyal D., Executive Officer, Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for SAVICELL's next move

See what Strategic adds

SAVICELL raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.